	Application No.	Applicant(s)
Notice of Allowability	10/509,253	NAKAMURA ET AL.
	Examiner	Art Unit
	Rebecca L. Anderson	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>2 March 2007</u> .		
2. The allowed claim(s) is/are 1-10, 14, 16 and 18-21, now renumbered as claims 1-16.		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 Nation of Informal D	Acad Acadhada
 Notice of References Cited (PTO-892) Notice of Draftperson's Patent Drawing Review (PTO-948) 	5. Notice of Informal Pa	• •
	 Interview Summary (Paper No./Mail Date 	e
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 	7. Examiner's Amendm	ent/Comment
 Examiner's Comment Regarding Requirement for Deposit of Biological Material 	8. 🖾 Examiner's Statement of Reasons for Allowance	
	9.	

Application/Control Number: 10/509,253

Art Unit: 1626

DETAILED ACTION

Claims 1-10, 14, 16 and 18-21 are currently pending in the instant application, appear allowable over the prior art of record and have been renumbered as claims 1-16. Applicants' amendment and remarks filed 2 March 2007 hav overcome the 35 USC 112 1st paragraph rejection and the 35 USC 112 2nd paragraph rejections. Experimental Example No. 4, page 59 of the specification, provides support for the treatment of retinal ischemic disorder.

Drawings

The drawings filed on 28 September 2006 are accepted.

Reasons for Allowance

The following is an examiner's statement of reasons for allowance. This invention relates to products of the formula (I) and methods of treating cataract or retinal ischemic disorder. The novel and nonobvious aspect of this invention involves the substituents on the morpholine ring. The closest prior art of record fails to teach or suggest applicants' instantly claimed formula (I).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rebecca L. Anderson whose telephone number is (571)

Application/Control Number: 10/509,253

Art Unit: 1626

272-0696. Mrs. Anderson can normally be reached Monday through Friday 5:30AM to 2:00PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Mr. Joseph K. McKane, can be reached at (571) 272-0699.

The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Rebecca Anderson
Patent Examiner
Art Unit 1626, Group 1620

Technology Center 1600

3/23/07

KAMAL A. SAEED, PH.D. PRIMARY EXAMINED

Joseph K. McKane

Supervisory Patent Examiner Art Unit 1626, Group 1620

Technology Center 1600